Assertio Therapeutics (ASRT) Prices 22.6M Share Registered Direct Offering at $0.62/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering
February 5, 2021 12:05 AM ESTLAKE FOREST, Ill., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 22,600,000 shares of its common stock at a purchase price of $0.62 per share in a registered direct offering. Â
Roth Capital Partners acted as the sole placement agent in connection with the offering.
The offering is expected to close on February 9, 2021, subject to customary closing conditions. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $14.0... More



